Economic burden of resected squamous cell carcinoma of the head and neck in a US managed-care population

Journal of Medical Economics

Volumn 14, Issue 4, 2011, Pages 421-432

  Amonkar, Mayur M ^a   Chastek, Benjamin ^b   Samant, Navendu ^b   Teitelbaum, April ^c  

^a GLAXOSMITHKLINE   (United States)

^b Health Economics and Outcomes Research   (United States)

^c Medical and Scientific Affairs   (United States)

Author keywords

Chemotherapy; Claims analysis; Cost of illness; Head and neck cancer; Outcomes assessment

Indexed keywords

ANTHRAQUINONE; ANTIMITOTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; BEVACIZUMAB; CETUXIMAB; DNA TOPOISOMERASE INHIBITOR; ERLOTINIB;

AMBULATORY CARE; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; EMERGENCY CARE; FOLLOW UP; HEAD AND NECK CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; LARYNX CANCER; LIP CANCER; MANAGED CARE; MOUTH CANCER; PHARYNX CANCER; POSTOPERATIVE CARE; SQUAMOUS CELL CARCINOMA; TONGUE CANCER; UNITED STATES;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; COSTS AND COST ANALYSIS; FEMALE; HEAD AND NECK NEOPLASMS; HEALTH SERVICES; HUMANS; INSURANCE CLAIM REVIEW; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; NEOPLASMS, SQUAMOUS CELL; RETROSPECTIVE STUDIES; UNITED STATES; YOUNG ADULT;

EID: 79960136789     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2011.584096     Document Type: Article

References (32)

1. Menzin J, Lines LM, Manning LN. The economics of squamous cell carcinoma of the head and neck. Curr Opin Otolaryngol Head Neck Surg 2007;15:68-73 (Pubitemid 46594856)
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30
3. Neville BW, Day TA. Oral cancer and precancerous lesions. CA Cancer J Clin 2002;52:195-215
4. Vokes EE, Weichselbaum RR, Lippman SM, et al. Head and neck cancer. N Engl J Med 1993;328:184-94
5. Lee JM, Turini M, Botterman MF, et al. Economic burden of head and neck cancer: a literature review. Eur J Health Econ 2004;5:70-80 (Pubitemid 38315901)
6. National Cancer Institute. Surveillance Epidemiology and End Results. Cancer of the larynx. Available at: http://seer.cancer.gov/csr/1975-2007/browse- csr.php?section12&pagesect-12-table.08.html
7. National Cancer Institute. Surveillance Epidemiology and End Results. Cancer of the larynx. Available at: http://seer.cancer.gov/csr/1975-2007/browse- csr.php?section20&pagesect-20-table.10.html
8. National Cancer Institute. Cancer Facts. Head and Neck Cancer: Questions and Answers. Available at: http://www.cancer.gov/cancertopics/factsheet/Sites- Types/head-and-neck Accessed April 4, 2011
9. Wineland AM, Stack Jr BC. Modern methods to predict costs for the treatment and management of head and neck cancer patients: examples of methods used in the current literature. Curr Opin Otolaryngol Head Neck Surg 2008;16:113-16 (Pubitemid 351354965)
10. Arthur G James Cancer Hospital & Research Institute. The James Line: Head and Neck Cancers. Available at: http://www.jamesline.com/headandneck/. Accessed June 23, 2010
11. Correa AJ, Burkey BB. Otolaryngology for the internist: current options in management of head and neck cancer patients. Med Clin North Am 1999;83:235-46 (Pubitemid 29031703)
12. Lester SE, Wigt RG. When will I see you again? Using local recurrence data to develop a regimen for routine surveillance in post-treatment head and neck cancer patients. Clin Otolaryngol 2009;34:546-51
13. Dubner S, Ostrower ST. Head and neck cancer - resection and neck dissection: treatment. eMedicine Updated April 3, 2008
14. Ang KK. Multidisciplinary management of locally advanced SCCHN: optimizing treatment outcomes. Oncologist 2008;13:899-910
15. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11:21-8
16. Murphy BA, Beaumont JL, Isitt J, et al. Mucositis-related morbidity and resource utilization in head and neck cancer patients receiving radiation therapy with or without chemotherapy. J Pain Symptom Manage 2009;38:522-32
17. Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide. IARC CancerBase no. 5. IARC: Lyon, 2001
18. Jovanovic A, van der Tol IG, Schulten EA, et al. Risk of multiple primary tumors following oral squamous-cell carcinoma. Int J Cancer 1994;56:320-3 (Pubitemid 24087621)
19. Posner MR. Adjuvant post-operative chemoradiotherapy in head and neck cancer: a standard of care? Oncologist 2005;10:174-5 (Pubitemid 40463153)
20. Posner MR. Paradigm shift in the treatment of head and neck cancer: the role of neoadjuvant chemotherapy. Oncologist 2005;10(Suppl 3):11-19 (Pubitemid 43152726)
21. Forastiere A, Koch W, Trotti A, et al. Head and neck cancer. N Engl J Med 2001;345:1890-900 (Pubitemid 33716564)
22. Hall SF, Groome PA, Rothwell D. Time to first relapse as an outcome and a predictor of survival in patients with squamous cell carcinoma of the head and neck. Laryngoscope 2000;110:2041-6
23. Groome PA, OSullivan B, Irish JC, et al. Glottic cancer in Ontario, Canada and the SEER areas of the United States: do different management philosophies produce different outcome profiles? J Clin Epidemiol 2001;54:301-15 (Pubitemid 32153873)
24. Epstein JP, Knight TK, Epstein JB, et al. Cost of care for early-and late-stage oral and pharyngeal cancer in the California Medicaid population. Head Neck 2007;29:948-58
25. Nijdam W, Levendag P, Noever I, et al. Cost analysis comparing brachytherapy versus surgery for primary carcinoma of the tonsillar fossa and/or soft palate. Int J Radiat Oncol Biol Phys 2004;59:488-94 (Pubitemid 38622605)
26. Davis GE, Schwartz SR, Veenstra DL, et al. Cost comparison of surgery vs organ presentation for laryngeal cancer. Arch Otolaryngol Head Neck Surg 2005;131:21-6 (Pubitemid 40105456)
27. Hopper C, Niziol C, Sidhu M. The cost-effectiveness of Foscan mediated photodynamic therapy (Foscan-PDT) compared with extensive palliative surgery and palliative chemotherapy for patients with advanced head and neck cancer in the UK. Oral Oncol 2004;40:372-82 (Pubitemid 38221384)
28. Kosuda S, Kosuda S, Kusano S, et al. Feasibility and cost-effectiveness of sentinel lymph node radiolocalization in stage N0 head and neck cancer. Arch Otolaryngol Head Neck Surg 2003;129:1105-9 (Pubitemid 37248312)
29. Speight PM, Palmer S, Moles DR, et al. The cost-effectiveness of screening for oral cancer in primary care. Health Technol Assess 2006;10:1-144
30. Zavras A, Andrepoulous N, Katsikeris N, et al. Oral cancer treatment costs in Greece and the effect of advanced disease. BMC Public Health 2002;19:12
31. Van Agthoven M, van Ineveld BM, de Boer MF, et al. The costs of head and neck oncology: primary tumours, recurrent tumours and long-term follow-up. Eur J Cancer 2001;37:2204-11 (Pubitemid 33001290)
32. Lang K, Menzin J, Earle CC, et al. The economic cost of squamous cell cancer of the head and neck: findings from the SEER-Medicare data. Arch Otolaryngol Head Neck Surg 2004;130:1269-75 (Pubitemid 39532259)